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PLATELET INDUCTION OF MONOCYTE TO DENDRITIC CELL 
DIFFERENTIATION.  Tyler S. Durazzo, Robert E Tigelaar, Carole L Berger, Michael 
Girardi, Richard L Edelson.  Department of Dermatology, Yale Cancer Center, Yale 
University, School of Medicine, New Haven, CT 
 
We hypothesized that activated platelets induce monocyte-to-dendritic cell (DC) differentiation.  
The aims of this study were to: (1) determine the role that platelets play, if any, in the signaling of 
monocyte to DC differentiation; (2) determine the mechanism of action by which platelets induce 
monocyte-to-DC differentiation. (3) Use this knowledge to advance cancer immunotherapy.   
 
To achieve these ends: (1) parallel-plate flow chambers were designed to deliver monocytes a 
controlled level of platelet exposure, with phenotype and genotype assessed following overnight 
incubation; (2) blocking antibodies and proteins were used to assess for the significance of 
particular monocyte-platelet interactions in the mechanism; (3) additional experiments and 
mathematical modeling was performed to extrapolate our new mechanistic knowledge to enhance 
extracorporeal photochemotherapy (ECP), an immunotherapy in clinical use. 
 
Results showed direct correlation between platelet exposure and level of DC differentiation 
following overnight incubation (p < 0.0001).  A detailed mechanism was determined involving p-
selectin and other proteins expressed by activated platelets.  This mechanistic knowledge permitted 
intelligent modification of ECP. 
We conclude that platelets induce monocyte to DC differentiation.  The rapidity and efficiency of 
this induction suggests the possibility that this is a physiologic mechanism employed in-vivo for 
DC differentiation.  Possible exploitation of this mechanism may prove beneficial in cancer 
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Due to high response rates and an excellent safety profile, extracorporeal 
photochemotherapy (ECP) is widely used for immunotherapy in patients with leukemic 
cutaneous T-cell lymphoma (CTCL), graft versus host disease, and organ transplant 
rejection [1].   Recently, it has been reported that ECP induces a high percentage of 
processed monocytes to enter the dendritic cell (DC) differentiation pathway, within a 
single day of treatment [2].  Despite intense research, the mechanism by which ECP 
induces this differentiation has remained elusive. 
 
Dendritic cells (DC) are the most potent antigen presenting cells in the human body, 
orders of magnitude more powerful than any other cell type know [3].  Their 
physiologic role has proven to be central to immune function.  Located at the interface 
between innate and adaptive immunity, DC orchestrate the immune system’s response 
via their influence on CD4+ T-cells, CD8+ T-cells, and other effector cell types [4].  
Their central role in the immune system has recently placed them at the forefront of 
cancer immunotherapy [5-7].   
We investigated the mechanism by which ECP induces monocyte-to-DC 
differentiation.  The efficiency and rapidity of this cellular conversion, occurring 
without addition of exogenous growth factors, suggests that the manner in which ECP 
induces monocytes to differentiate into DC may result from the co-opting of a normal 




molecular basis for ECP’s influence on monocytes may provide important clues about 
in-vivo DC generation. 
 
To investigate this phenomenon, we developed an ECP model which could be 
visualized with digital microscopy and therefore permit direct visualization of the 
cellular components and flow dynamics involved.  We report in this thesis that 
activated platelets induce monocyte-to-DC differentiation under flow conditions 
mimicking those found in post-capillary venules.   
 
1.2 Physiologic Dendritic Cell Development  
Relatively little is known regarding DC development in comparison to other cells of 
haemotopoietic origin.  Based on evidence mainly from mouse models, current theories 
propose that most DC develop in vivo from hematopoietic stem cell-derived 
progenitors with both lymphoid and myeloid-restricted differentiation potential [8].  
One common precursor is believed to give rise to monocytes, macrophages, and 
dendritic cells in the bone marrow.  Furthermore, some monocytes possess the 
potential, after leaving the bone marrow, to differentiate under inflammatory conditions 
into both DC and macrophages [9].  It is this DC differentiation from peripheral blood 
monocytes which is of particular relevance to this thesis.   
 
Much work remains to be done in terms of elucidating the in-vivo factors responsible 
for inducing peripheral blood monocyte-to-dendritic cell differentiation.  Part of the 




monocyte populations, as well as inconsistencies among studies done in-vivo versus in-
vitro [9-11].  These inconsistencies, however, have drawn attention to the likelihood 
that physiologic monocyte-to-DC differentiation in-vivo is dependent on both intrinsic 
monocyte potential as well as factors acting upon the monocyte.   
 
There exists clear evidence that human blood monocytes are heterogeneous: expressing 
different proteins, responding differently to various stimuli, and producing different 
products [11].  In vivo studies have provided evidence that two monocyte 
subpopulations, Ly6C+ and Ly6C-, apparently have separate potentials, regardless of 
the factors acting upon them [12-15].  Ly6C+ monocytes appear capable of 
differentiation into DC, Langerhans cells, inflammatory macrophages, or myeloid-
derived suppressor cells; Ly6C- monocytes appear to have the potential to differentiate 
into alveolar macrophages [9]. 
 
In vitro studies have provided evidence for environmental factors that contribute to DC 
differentiation.  Exposing both human and mouse monocytes to suprapharmacologic 
doses of IL-4 and GM-CSF for long periods in culture results in differentiation into 
DC, regardless of the monocyte subset [10, 16, 17].  Furthermore, addition of TGF-1 
to the cultures results in Langerhans cell differentiation [18].  In contrast, addition of 
IL-6 to the same cultures results in macrophage, not DC, differentiation [19].   
Exposing monocytes to M-CSF in vitro also results in macrophage differentiation [18].  




M1 or M2-subtype  macrophages by addition of either IFN-gamma or IL-4, 
respectively [20, 21].   
 
It is clear that in vitro, monocyte differentiation is influenced heavily by the cytokine 
environment, albeit only to suprapharmacologic doses.  How to precisely extrapolate 
these findings to physiologic in-vivo mechanisms of monocyte-to-DC differentiation 
remains to be determined.  Additionally, functional differences between those in-vitro 
generated cells and their in-vivo counterparts have not yet been fully explored.  As 
outlined in section 1.4, DC generated using in-vitro suprapharmacologic cytokines 
have been relatively unsuccessful at reaching the theoretical potential DC posses in 
cancer immunotherapy.  
 
1.3 Extracorporeal Photochemotherapy (ECP) 
ECP is the first FDA approved cellular immunotherapy, originally introduced in 1987 
for the treatment of patients with severe CTCL [22].  Since its initial introduction, the 
therapy’s clinical application has been extended to include successful treatment of 
patients with chronic graft-versus host disease (GVHD), and prevention of organ 
transplant rejection [23, 24].  The therapy’s high clinical success rate in otherwise 
therapeutically resistant situations, in addition to its low toxicity [25], has led to the 
therapy being used over 1.5 million times in over 150 centers throughout the world.  
Despite the therapy’s clinical success, its precise mechanism of action has remained 




differentiation, however the mechanism responsible for this induction remains 
unidentified [1, 2].  
 
The therapy consists of collecting a small number (<10%) of a patient’s lymphocytes 
via leukophersis of peripheral blood.  8-methoxypsoralen (8-MOP) is then added to 
these collected cells (suspended in plasma), followed by passage of the cells through a 
1-mm space located between two transparent plastic plates.  While the cells are passed 
through the transparent plates, they are irradiated with UVA energy, causing 8-MOP to 
become activated and covalently crosslink thymine bases of DNA [26]; this 
crosslinking causes a fraction of cells to undergo apoptosis.  The therapy is completed 
by reinfusing the treated cells into the patient. 
 
Interestingly, the treatment is conducted identically as described for both CTCL (a 
cancer expected to respond to immunostimulation), as well as GVHD (a condition 
expected to positively respond to immunosuppression).  The seemingly paradoxical 
ability of the same treatment to invoke immunotherapeutic responses at both ends of 
the spectrum is consistent with ability of the treatment to generate fully functional 
dendritic cells; dendritic cells are well known for their physiologic capacity to 
orchestrate immune responses in either direction, depending on stimuli encountered in 
the body [4].             
 
The DCs generated by ECP have been shown to be functionally capable of processing 




analysis have shown that ECP-processed monocytes show expression profiles 
consistent with functional DC, with up or down regulation of more than 1100 genes 
[2].  Dramatic increases in surface expression of proteins critical to DC function have 
also been documented in DC generated by ECP.  Interestingly, all these changes 
described occur in less than 18 hours after treatment, without the need for any 
exogenous cytokines or growth factors. 
 
The time course of DC induction, the non-requirement for exogenous growth factors, 
and the clinical success, all suggest that the ECP may be recapitulating a physiologic 
mechanism of DC generation.  Therefore, study of ECP’s unknown mechanism of DC 
induction may provide insight into physiologic principles of DC generation.  
Furthermore, if these principles are uncovered, improvements to the ECP system may 
be made which allow for better control, greater influence, and higher DC yields.        
 
1.4 Dendritic Cells and Cancer Immunotherapy 
DCs’ central role in the immune system has placed them at the forefront of cancer 
immunotherapy.  Recent years have seen an increase in attempts at generating DC for 
the purpose of inducing clinical immunity against various cancers [5-7].  These 
therapeutic protocols have thus far not lived up to the theoretical potential DCs 
possess.  One potential explanation for the relative lack of successes is that the vast 
majority of protocols are based on generating DC from monocytes by administering 
suprapharmacologic doses of cytokines and growth factors, for instance, CM-CSF and 




functional correspondence among DC generated in this manner in comparison to those 
generated physiologically is unknown.  A better understanding of physiologic 
principles of DC generation may allow for their theoretical potential of generating 
cancer immunity to be better realized.       
 
1.5 Platelets and Immunobiology 
Platelets are well recognized for their main role in thrombus formation and 
maintenance of hemostasis.  However, a comparatively recent body of literature has 
revealed an additional relevant function in immunobiology [28, 29].   
 
Platelets are cell fragments derived from the cytoplasm of megakaryocytes in the bone 
marrow.  While only approximately 2 microns in diameter, they circulate at levels of 
approximately 300,000/l in healthy individuals, making their total volume greater 
than any other leukocyte subset [30].  In addition, due to physical properties of flow 
dynamics in blood vessels (see Appendix A), their relatively small size places them 
more proximal to the endothelium than any leukocyte population, making them ideal 
for immune surveillance.   
 
Studies have shown that inflammation within tissue leads to an imbalance of 
procoagulant and anticoagulant properties of the local endothelium, resulting in platelet 
recruitment and activation [29].  For instance, one of the first pro-inflammatory 
cytokines released at sites of tissue infection is TNF-alpha; this molecule has been 




simultaneously inducing TF production on the endothelium [32].  This results in 
thrombin activation and fibrin formation, which in turn recruits and activates platelets.  
Interestingly, TNF-alpha concurrently causes nitric oxide (NO) release from 
endothelium [33].  NO is a potent inhibitor of platelet aggregation; thus, TNF-alpha is 
able to delicately recruit and activate platelets to sites of inflammation while 
simultaneously preventing thrombus formation, which would likely prove detrimental 
to leukocyte recruitment by limiting perfusion of the inflamed region.  
 
Activated platelets have been found to express and secrete a number of ligands and 
substances capable of recruiting and activating leukocytes, including p-selectin [29], 
CD40L [34], IL-1B [35], CCL5, and CXCL4 [36].  Complex interactions among 
platelets and leukocytes have been found to contribute to various immune processes, 
including progression of atherosclerotic lesions [37], wound healing [38], and atopic 
dermatitis [30].  While the body of literature implementing platelets in key 
immunologic roles continues to mount, a role in inducing monocyte-to-DC 




HYPOTHESIS AND SPECIFIC AIMS 
 
The initial aim of the work presented in this thesis was to determine the mechanism 
behind ECP’s induction of monocyte to dendritic cell differentiation.  As described in 
the results section, preliminary experiments suggested a role for platelets, subsequently 
leading to our main hypothesis: platelets induce monocyte-to-dendritic cell 
differentiation. 
 
The subsequent aims of the work presented in this thesis were to: (1) determine the role 
that platelets play, if any, in the signaling of monocyte to dendritic cell differentiation; 
(2) determine the mechanism of action in which platelets induce monocyte-to-dendritic 
cell differentiation; and (3) use the mechanistic knowledge gained to intelligently 
advance ECP with the hope of potentially extending its scope in cancer 






Statement of author’s contribution: All work composing this thesis and presented in 
the subsequent sections was performed by the first author of the thesis. 
Obtainment of leukocytes and platelets: All samples were acquired from young, 
healthy subjects not taking medication, including aspirin, known to influence platelet 
function.  Samples were obtained under the guidelines of the Yale Human 
Investigational Review Board. Informed consent was provided according to the 
Declaration of Helsinki. Peripherial blood specimens were collected through a 19-
gauge needle from the antecubital vein into syringes containing heparin, then layered 
on Ficoll-Hypaque (Gallard-Schlessinger, Carle Place, N.Y.).  Following centrifugation 
at 180g, the interface containing the mononuclear leukocyte fraction was collected and 
washed twice in HBSS, then resuspended in RPMI-1640 medium (GIBCO) to a final 
concentration of 5 * 10
6
 mononuclear cells/ml.  Experiments with the obtained cells 
were performed within one hour of being acquired.    
 
Preparation of Platelet-rich-Plasma: Whole blood was centrifuged at 150 g for 15 
min at room temperature.  The platelet-rich-plasma (PRP) layer was collected and 
centrifuged at 900 g for 5 min, and the platelet pellet resuspended in RPMI 1640 to the 
desired concentration. 
Preparation of Parallel-Plates: Two types of parallel-plate flow chambers were used 
to model the flow dynamics of ECP.  Experiments involving the assessment of cell-




Rockville, MD).  This system consisted of a volumetric flow path measuring 20000 x 
10000 x 254 microns (length x width x height).  The bottom plate in this system was 
composed of a 15mm petri dish (BD Biosciences, Durham, NC) separated by a gasket 
and vacuum-connected to an acrylic flow deck, which formed the upper plate.  For 
experiments requiring the plates to be pre-coated with platelets, prior to assembling the 
flow chamber, 20 drops of the desired concentration of PRP was placed in the center of 
the petri dish and platelets allowed to settle for 20 minutes at room temperature.  The 
petri dish was washed with 2ml of RPMI twice, and the flow chamber then assembled. 
 
For experiments not involving the collection and phenotyping of cells post-flow, 
Vena8 biochips (Cellix Ltd, Dublin, Ireland) were used to generate laminar flow.  The 
volumetric flow path for a channel of the Vena8 biochips measured 20000 x 400 x 100 
microns (length x width x height).  Protein coating of these chips are described in the 
appropriate section below. 
 
Experiments using Parallel-Plates:   In all cases, the parallel-plate flow chamber was 
mounted on the stage of a phase contrast optical microscope (CK40, Olympus, Japan) 
with a 10x objective.  All runs were performed at room temperature. A uniform laminar 
flow field was simulated by use of a syringe pump (KD Scientific, New Hope, PA) 
capable of generating near-constant volumetric flow rates.  The components of the 
configuration were set up to minimize tubing.  Prior to infusing cell suspensions 
through the plates, the configuration was washed with 5 ml of RPMI at a flow rate 
producing a wall shear stress of approximately 1 dyne/cm
2




interest were then sent through the chamber at a fixed flow rate and wall shear stress 
(see Appendix A). 
All experiments were viewed in real time while in progress, and recorded using a DP 
200 digital camera and software (DeltaPix, Maalov, Denmark) at 15.2 frames per 
second.  When applicable, images were analyzed using Image J software (NIH).
  
Overnight culture: When overnight culture was desired, cells were centrifuged and 
resuspended in RPMI-1640 medium (GIBCO), supplemented with 15% AB serum 
(Gemini Bio-Products) to a final concentration of 5 x 10E6 cells/ml.  Cells were 
cultured overnight for 18 hours in 12-well polystyrene tissue culture pates (2 ml per 
well) at 37 degrees C with 5% CO2.  
 
Immunophenotyping: Monoclonal antibodies for immunophenotyping included 
CD14 (LPS receptor; monocytes), CD11c (integrin subunit; monocytes and DC), HLA-
DR (class II MHC molecule), CD83 (DC marker), CD62p (P-selectin; activated 
platelets), and CD61 (integrin subunit; platelets).  Antibodies were obtained from 
Beckman Coulter (CD14, CD11c, HLADR, CD83) or Sigma (CD62p, CD61) and used 
at their pre-determined optimal dilutions. Background staining was established with 
appropriate isotype controls, and immunofluorescence was analyzed using a FC500 
flow cytometer (Beckman Coulter).  Two-color membrane staining was performed by 
adding the pre-determined optimal concentrations of both antibodies directly 
conjugated to FITC or PE and incubating for 20 min at 4°C, followed by washing to 




performed following manufacturer’s instructions for cell fixation and permeabilization 
(Intraprep kit, Beckman Coulter). 
 
Quantitative real-time PCR: Gene expression was compared between cells exposed 
during flow through the parallel plates to low (10 + 5/low power field [lpf’]) verses 
high (102 + 32/lpf) levels of platelets, followed by overnight culture.  Cell RNA was 
isolated using RNeasy Mini Kit columns with on-column
 
DNase I treatment 
(QIAGEN).  RNA yield and purity were measured
 
using the NanoDrop ND-1000 
Spectrophotometer and the Agilent
 
2100 Bioanalyzer.  RNA was reverse transcribed to 
cDNA using
 
the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems).
 
Reverse transcription was carried out in a 96-well thermocycler
 
(MJ 
Research PTC-200) in the following conditions: 25°C,
 
10 minutes, 37°C, 120 minutes, 
85°C, 5 seconds. TaqMan
 
real-time PCR was used to detect transcripts of DC-LAMP, 
CD40, ADAM Decysin, Lox1, CCR7,
 
CD80, CD83, CD86, FPRL2, and GPNMB. 
Primers and probes for each sequence were
 
obtained as inventoried Taqman Gene 
Expression Assays (Applied
 




Co-cultures of Platelets with Monocytes:  Experiments involving co-cultures of 
monocytes with additional platelets were performed as described in the Overnight 
Culture section, with a few necessary modifications.  Following Ficoll-Hypaque 
separation, mononuclear cells were resuspended in 30% AB serum/RMPI to a final 
concentration of 10 x 10
6




well plate.  An additional 1ml or platelets (suspended in RPMI, at 2x the desired end-
concentration) or RPMI without platelets was then added to each well.  To activate 
platelets, 500 l containing 2 units of thrombin was added to half the wells, and 500 l 
of RPMI was added to the others to balance volume.  Cells were then incubated as 
described previously.      
     
Platelet Adhesion Studies: Platelet adhesion experiments were performed using the 
Vena8 flow chamber described above.  Fibrinogen and fibronectin (Sigma) were 
dissolved in PBS to a final concentration of 200 g/ml.  Channels of the Vena8 chips 
were incubated at room temperature in a humidified chamber for 2 hours with the 
protein solution, autologous plasma, or PBS alone.  The channels were washed with 5x 
the volume RPMI.  Platelet-rich-plasma was then perfused through the protein-coated 
channel at the indicated shear-stress, held constant.  For each channel, still images were 
acquired exactly 90 seconds into the experiment at 4 pre-defined low power fields 
located along the flow path (fields were centered at 2500, 7500, 12500, and 17500 
microns from the start point of infusion).   
 
Some experiments involved pre-treating platelet-rich-plasma (PRP) with protein 
fragments prior to infusion through the channels.  Small RGD peptides containing the 
amino-acid sequence Arg-Gly-Asp-Ser, DRG peptides containing the amino-acid 
sequence Ser-Asp-Gly-Arg, or fragment 400-411 of fibrinogen containing the amino-




a concentration of 2mM with PRP for 20 minutes at room temperature.  The PRP was 
then perfused through the channels as previously described.   
 
Receptor-Ligand Studies:  Same protocol followed as described in appropriate 
sections above, with a few necessary modifications.  Vena8 platelet-coated channels 
were pre-treated with either 40 g/ml anti-p-selectin (R&D Systems) or 40 g/ml of an 
isotype control for 30 minutes at room temperature, then washed with 5x the volume 
RPMI.  Mononuclear cell suspensions were pre-treated with either RGD peptides or 
DGR peptides at a concentration of 2.5 mM.  Video samples lasting 400 frames (26.3 
seconds) were recorded 60 seconds after commencement of flow using a lower power 
field of view spanning 400 microns and centered at 7500 microns from the flow start 
point.         
 
Studies aimed at assessing the protein conformation of beta-1 integrins were conducted 
using the Glycotech flow chamber.  15mm platelet-coated petri dishes (as described in 
section above) were pre-treated with 40 g/ml p-selectin or an isotype control for 20 
minutes at room temperature, then washed with 5x the volume RPMI.  Immediately 
following perfusion through the platelets, cells were immunophenotyped with anti-
CD29 HUTS-21 (BD Biosciences), an antibody that specifically binds to the active 
conformation of 1 integrins. 
 
Full-Scale-ECP: Leukocytes were collected as described above.  A full-scale ECP 




LS), permitting the repetitive circulation of cell-suspensions through the plate for at 
room temperature.  When indicated, ECP exposure plates were pre-incubated with 
platelet-rich-plasma for 15 minutes prior to the infusion of cell-suspensions.  Cell 
suspensions were circulated for 45 minutes at volumetric flow rates of either 100 
ml/min or 24.2 ml/min, followed by 30 seconds at 280 ml/min and collection (see 
Appendix A).  Cells were incubated overnight and phenotyped as described in the 







Monocytes in flow transiently interact with immobilized platelets 
ECP was initially developed as a means to enable extracorporeal chemotherapeutic 
exposure of pathogenic leukocytes to ultraviolet A (UVA)-activated 8-
methoxypsoralen (8-MOP), a DNA-cross-linking drug.  Therefore, ECP involves the 
flow of leukapheresed blood between large transparent plastic parallel-plates separated 
by 1 mm.  To permit detailed analysis of the flow dynamics involved during ECP, 
independent of UVA/8-MOP exposure, we reproduced the flow conditions of ECP 
using miniature parallel plates with surface area of only 0.8 mm
2
, separated by 100 
microns.  This model permitted visualization using digital microscopy.  Studies using 
the model (see Supplement 1 for video) revealed the following sequence occurring in 
ECP:  initial adherence of platelets from the flow stream to the plastic plate, followed 
by transient binding of passaged monocytes to the immobilized platelets.   
 
DC induction correlates with the number of monocyte-platelet interactions 
Based on the initial qualitative observations described above, platelets were 
hypothesized to contribute substantially to ECP’s induction of DC.  To test the 
influence of platelets on monocyte-to-DC differentiation, monocytes were passed 
between parallel plates pre-coated with autologous platelets at low (10 + 5/low power 
field [lpf]), medium (44 + 20/lpf), and high (102 + 32/lpf) densities.  The number of 
monocyte-platelet interactions per unit time increased in proportion to augmented 




monocyte interactions per lpf per second were observed with the high-density plate, 
dropping to 18.3 + 14 and 3.4 +1 interactions per second with the medium and low-
density plates, respectively (Figure 1A).  Following overnight incubation, a correlation 
was found between frequency of platelet-monocyte physical interactions in the plate 
and the proportion of cells expressing the DC phenotype (Figure 1B).    As the number 
of platelet-monocyte interactions increased, so too did the proportion of cells 
expressing markers consistent with DC differentiation, membrane HLA-DR and CD83: 





 after overnight incubation, in comparison to 4.9% and 0.8% 






Figure 1.  Effect of platelet density on number of platelet-monocyte interactions and 
subsequent monocyte phenotype. Monocytes were passed through parallel plates 
coated with platelets at low, medium, or high density.  (A) The number of platelet-
monocyte interactions increased substantially for plates coated with higher densities of 
platelets.  (B) After overnight incubation, monocytes which were exposed to high 
levels of platelets were significantly more likely to develop a phenotype consistent 
with DC differentiation, as assessed by expression of membrane CD83 and HLA-DR 
(high versus medium or low density: p <0.0001; medium versus low density: p < 










Monocyte exposure to platelets results in changes in gene expression 
To supplement the described changes in monocyte phenotype observed following 
platelet exposure, RT-PCR was performed to assess for changes in gene expression.  
Monocytes were passed through parallel plates coated with high or low densities of 
platelets as described in the previous section.  Following overnight incubation, RNA 
was extracted and RT-PCR performed to determine level of expression for 10 genes 
associated with DC (Figure 2).  CD40, a costimulatory molecule with known 
expression on mature DCs [39], was found to be upregulated by over 567% in 
monocytes exposed to high densities of platelets relative to monocytes exposed to low 
levels.  LAMP3, a marker specific to DC differentiation [40], was upregulated by 
398%.  CD80, a costimulatory molecule known to be upregulated upon APC activation 
[41], was found upregulated by 220% in monocytes exposed to high levels of platelets.  
CCR7, a chemokine receptor known to play a role in DC migration to lymphoid 
organs, was upregulated by 376%.  LOX1, CD83, CCR7, and ADAM Decysin, all 
genes associated with DC [2], were upregulated in the monocytes exposed to high 
levels of platelets.  FPRL2, GPNMB, and CD86 were all downregulated in monocytes 
exposed to high levels of platelets.  FPRL2 is a receptor that when activated is known 
to inhibit DC maturation [42]; GPNMB is a protein involved in decreasing cytokine 





Figure 2.  Gene expression following exposure to platelets.  Monocytes were exposed 
to high or low levels of platelets in flow.  Following overnight incubation, cells were 
assessed for differences in gene expression using RT-PCR.  Figure shows gene 
expression changes in monocytes exposed to high levels of platelets relative to those 
exposed to low levels.  Seven genes associated with DC-differentiation and/or function 
were found to be upregulated, while three were downregulated.  Of the genes 
downregulated, GPNMB and FPRL2 have known functions in decreasing cytokine 
production and inhibiting DC maturation, respectively.  Of the genes upregulated, all 
have either pro-immune functions or miscellaneous roles in DC biology.  See text for 
specific description of genes.   
  
DC induction did not occur under static conditions in the presence of platelets  
Platelets could potentially influence monocytes through direct receptor-ligand 
interaction, or via cytokines and other secreted mediators.  Furthermore, it is well 
known that formation of receptor-ligand bonds in flowing systems is influenced by 
shear forces [44, 45].  Accordingly, we next tested whether flow dynamics were 
required for platelet-dependent induction of monocytes in this system.    To determine 
whether the platelet induction of monocyte-to-DC differentiation requires flow 








) and high 
(>400,000/mm
3
) concentrations of platelets, with platelets in either an inactive or 
active state (induced by the addition of thrombin).  After overnight incubation in static 
conditions (shear stress = 0), we found that neither activated nor non-activated platelets 
were capable of inducting DC differentiation of monocytes in the absence of flow 
(Figure 3).    
 
Figure 3.  Platelet influence on monocyte differentiation in static conditions.  
Monocytes were co-cultured for 18 hours with low, medium, or high concentrations of 
platelets in static conditions lacking flow.  Under these conditions, there was no 
observable platelet influence on DC differentiation; all conditions resulted in low, 
basline levels of cells expressing DC markers.  Furthermore, activating platelets with 
thromin in culture (blue line) did not cause a discernable difference in monocyte 
differentiation relative to those cultures containing plaetlets not activated by thrombin 







Platelets suspended in flow bind to serum proteins adsorbed onto the plate 
A range of proteins abundantly present in plasma, including fibronectin and fibrinogen, 
are well known to adsorb onto glass and plastic surfaces; we therefore assessed the 
contribution of plastic-adherent plasma proteins on platelet adhesion and activation.  
Plastic parallel plates were pre-coated with either fibrinogen, fibronectin, plasma, or 
saline.  Unactivated platelets were then passed through at shear rates producing wall 
shear stresses ranging from 0.2 to 6.0 dyne/cm
2
 (encompassing the relevant ECP range, 
see Appendix A).  The highest concentrations of platelets adhered to plates coated with 
fibrinogen (Figure 4a).  Adhesion to fibronectin-coated, plasma-coated, and uncoated 
plates was observed as well, but to a significantly lower extent at all shear levels below 
2.5 dyne/cm
2
 (p < 0.01).  In the absence of flow, platelet adherence was equivalent on 
all protein substrates (data not shown). 
Both fibrinogen and fibronectin contain segments with the amino acid sequence 
arginine(R)-gylcine(G)-aspartate(D), RGD.  RGD segments are well-known to interact 
with many integrin receptors, particularly the I/A domain of beta subunits, which are 
exposed when the integrins are in the active conformation [46].  In experiments using 
fibrinogen-coated plates, platelet adhesion was not significantly altered by pre-
incubation of platelets with RGD peptides; however,  adhesion was significantly 
decreased (p < 0.05) by pre-incubation of platelets with peptide fragments 
corresponding to amino acids 400-411 of fibrinogen, the gamma component of the 
protein (Figure 4b, left panel).  In experiments using fibronectin-coated plates, pre-




while pre-incubating platelets with peptide fragments corresponding to amino acids 
400-411 of fibrinogen had no effect (Figure 4b, right panel).  Interestingly, it should be 
noted that unlike the I/A domain of integrins, which is known to interact with RGD 
domains of proteins, the region of the intergrin found to interact with the gamma 
component of fibrinogen is exposed in the intergrin’s inactive state.  Therefore, this 
data suggests that unactivated platelets in flow bind to the gamma-component of 
fibrinogen-coated plates.  The potential for platelets in the unactivated state to bind 
fibrinogen may explain the greater level of platelet adhesion seen on fibrinogen coated 





Figure 4.  Plasma protein influence on platelet adhesion to plastic plates.  (A) Platelets 
were passed through plates coated with fibrinogen (blue), plasma (red), fibronectin 
(purple), or RMPI (green) at the shear stress level indicated by the x-axis.  Platelets in 
flow adhered optimally to fibronectin.  For all proteins, platelet adhesion occurred 
maximally between 0.5 and 1.0 dyne/cm
2
.  (B) Platelets were pretreated with either 
RGD fragments (+RGD) or gamma fragments (+Gamma) and their subsequent 
adhesion to fibrinogen (left panel) and fibronectin (right panel) was assessed.  Platelet 
binding to fibrinogen was decreased by gamma fragments (p < 0.05), while binding to 






Platelets are activated by adhesion to the plate 
Platelets physiologically circulate in an inactive state, with an array of proteins 
contained in intra-cellular granules, upon encountering stimuli such as damaged 
endothelium or thrombin, platelets become activated and translocate these intracellular 
proteins to the plasma membrane almost instantaneously [47].  We postulated that 
platelet adhesion to the plastic plate/absorbed proteins caused platelet activation similar 
to that caused by well-known stimuli.  To test this hypothesis, we assessed surface 
expression of p-selectin, a well-known marker of platelet activation, before and after 
adhesion.  Prior to adhesion, 6 + 3% of platelets were found to express p-selectin, with 
a mean fluorescence intensity (MFI) of 12.4 + 6.9; following adhesion, p-selectin 
positivity increased to 64 + 13% (MFI 98.2 + 14).  The positive control consisted of 
platelets activated with thrombin and was found to be 71 + 18 % p-selectin positive 
(MFI 108.3 + 23).  Since the clinical ECP procedure can often last longer than 60 
minutes, expression of p-selectin was further assessed at 30, 60, and 90 minutes 
following adhesion.  P-selectin expression was found to remain stable at all time 
points, with 72 + 11% of platelets p-selectin positive 90 minutes after adhesion, 
indicating that platelets remain in an active state for the duration of the clinical 
procedure.  Similar trends were found in assessment of IIb-3, a fibrinogen-binding 
integrin, with surface expression of this protein increasing significantly following 





Monocytes interact with p-selectin and RGD-containing ligands expressed on 
activated platelets 
The monocyte-platelet interactions observed on video were divided into two categories: 
(1) short-acting, defined as contact occurring for less than 3 seconds (48 frames), and 
(2) long-acting, defined as contact longer than 3 seconds, including stable binding.  
Since we previously determined that the platelets in the ECP system were in an 
activated state, and activated platelets express an array of proteins including p-selectin 
and RGD containing proteins (e.g.fibronectin, fibrinogen, and vitronectin), we sought 
to determine the involvement, if any, of these proteins in either short or long-duration 
interactions.  Plastic plates were pre-coated with platelets, and 4 conditions tested: (1) 
platelets pre-treated with an irrelevant isotype control, and monocytes untreated 
(P+RGD+); (2) platelets pre-treated with an irrelevant isotype control, and monocytes 
pre-incubated with RGD peptides (P+RGD-);  (3) platelets pre-treated with anti-p-
selectin, and monocytes untreated (P-RGD+); (4) platelets pre-treated with anti-p-
selectin, and monocytes pre-treated with RGD peptides (P-RGD-).  Pre-treating 
monocytes with RGD peptides should result in a decreased in the number of free RGD-
recognizing receptors available to interact with RGD-containing proteins expressed by 
the platelets.  Thus, the four conditions tested represent every permutation of potential 
interaction with 2 platelet ligands: p-selectin and RGD-containing-proteins.   As shown 
by Figure 5, both short-acting and long-acting interactions were maximal when neither 
RGD nor p-selectin were blocked (P+RGD+), and the level of interaction in all other 
conditions was expressed as a percentage of this maximum.  Blocking with anti-p-




platelet interactions to almost zero (p < 0.01, Figure 6, Supplements 3 for video).  In 
contrast, blocking RGD along (P+RGD-) did not significantly alter the number of 
short-duration interactions, but decreased the long-duration monocyte-platelet 
interactions by 44% (p < 0.05, Figure 6).  Blocking both p-selectin and RGD 
simultaneously (P-RGD-) resulted in a pattern similar to that seen when only p-selectin 
was blocked, with both long and short duration interactions reduced to near zero.   
The logical conclusions which are most appropriate, based on the pattern of 
interactions observed in each of the four conditions, are as follows: (1) p-selectin is 
predominantly responsible for the short-duration interactions; (2) RGD-containing 
proteins expressed by the platelet are involved in long-duration interactions, but not 
short-duration interactions; (3) monocyte interaction with p-selectin must occur 
upstream of monocyte interaction with RGD-containing proteins expressed by 
platelets.  Conclusion (3) immediately above is based on the observation that 
conditions of P-RGD+ decreased both short and long duration interactions to near zero, 
while P+RGD- conditions only influenced (decreased) long-duration interactions.  If 
there was no sequentiality involved in the interactions, then given that P+RGD- only 
resulted in a decrease in long-duration interactions, conditions of P-RGD+ should have 
produced similar results to P+RGD+ in terms of long-duration interactions.  
Furthermore, the ordering of the interactions, i.e. that p-selectin acts upstream of RGD-
interactions, is apparent by the finding that conditions of P+RGD- only influenced long 
duration interactions, while conditions of P-RGD+ produced similar results to those of 





Figure 5. Proteins involved in platelet-monocyte interactions. Monocytes were passed 
between platelet-coated plates at a wall shear stress of 0.5 dyne/cm
2
 under the 
conditions indicated by the x-axis: platelets were either pretreated with anti p-selectin 
(P-) or an isotype control (P+); monocytes were either pretreated with RGD peptides 
(RGD-) or a control fragment (RGD+).  Platelet-monocyte interactions were quantified 
under each set of conditions using digital microscopy, and are expressed in the figure 
as a fraction of the maximum seen under conditions of P+/RGD+.  Interactions were 
divided into those lasting less than 3 second (short duration, blue bars) and those 
lasting greater than 3 seconds, including stable binding (long-duration, red-bars).  All 
conditions which involved blocking with anti-p-selectin (P-) resulted in a significant 
decrease in both short and long duration interactions (**, p < 0.01); Blocking only 
RGD (RGD-) resulted in a significant decrease in long-duration interactions (*, p < 









Monocyte exposure to P-selectin results in downstream monocyte integrin-activation  
Integrin receptors, in their open conformation, are known to interact with RGD-
containing ligands [48].  Using an antibody that recognizes an epitope exposed only 
when the 1 integrin is in its open conformation, we assessed the conformation of 
monocyte integrins before and after flow through the ECP model.  Figure 6 shows that 
as the number of short-acting monocyte-platelet interactions increased, there was 
corresponding increase in the percentage of monocytes expressing integrins in their 
open conformation immediately post-flow.  The blue line shows that an average of 
71% of monocytes which had received a high number of platelet-interactions (> 61+ 19 
/lpf x sec) expressed 1 in the active form, in comparison to 9% monocytes which 
received a low number of platelet interactions (< 5.1 + 2 /lpf x sec).  These results were 
not significantly affected by pre-treating the adherent platelets with an irrelevant 
isotype control (red line).  In contrast, pre-treating platelets with anti-p-selectin reduced 
the platelet-monocyte interactions to near zero, and monocytes emerging from flow in 
these conditions (green line) displayed low levels of active 1 integrins, irrespective of 
the density of platelets to which they were exposed.  It is noteworthy that all cell 
populations prior to passage through the plates demonstrated similar low levels (data 
not shown) of baseline integrin activation; therefore, differences seen in short-duration 
monocyte-platelet interactions were not the result of differences in integrin 





Figure 6. Effect of p-selectin exposure on monocyte intergrins.  Plastic plates were 
coated with platelets at the relative density indicated by the x-axis.  Platelets were then 
pretreated with anti p-selectin (green line) or an isotype control (red line), or received 
no pretretment (blue).  Monocytes were passed through the plates at 0.5 dyne/cm
2
 and 
then immediately assessed by flowcytometry for expression of active 1 integrins.  The 
y-axis indicates the percent of monocyte which bound an antibody directed at an 
epitope only exposed when the integrin is in the open confirmation.   
 
Monocyte exposure to P-selectin required for DC differentiation 
Given the dependence of platelet-monocyte interactions on platelet p-selectin, we set 
out to determine if there was a relationship between monocyte exposure to p-selectin at 
time 0, and the phenotype later developed by the monocyte after overnight incubation, 
time 18-hours (Figure 7).    Monocytes were passed though parallel plates coated with 
high densities (108 + 36/lpf) of platelets that were either untreated (unblocked), or 
pretreated with either anti-p-selectin or an isotype control.  On average, 15.5 + 4 % of 








(markers of maturing DC) after overnight incubation, and 13 + 4 % of the those 
exposed to platelets blocked with the irrelevant isotype control.  In stark contrast, only 
3 + 2% of the those monocytes exposed to platelets blocked with anti-p-selectin 
became HLA-DR+/CD83+ after overnight incubation.    
 
Figure 7. Effect of p-selectin exposure on monocyte phenotype after overnight 
incubation.  Platelet-coated plates were either untreated (first column), or pretreated 
with an isoptype control (second column) or anti p-selectin (third column).  Monocytes 
were passed through the plates at 0.5 dyne/cm
2
 then incubated overnight.  The y-axis 













Enhancement of ECP’s DC-generating capacity 
Since our data indicate that platelets induce monocyte-to-DC differentiation, the 
following changes were incorporated into the traditional clinical ECP system to 
maximize monocyte interactions with platelets:   
First, experiments and mathematical calculations determined that the optimal 
volumetric flow rate for maximizing monocyte-platelet interactions in the ECP 
apparatus was 24 ml/min (as opposed to currently used clinical value of 100 ml/min).  
Details pertaining to this determination can be found in Appendix A. Briefly, this value 
was determined by (1) experimental evidence that monocyte-platelet interactions 
preferentially occur at wall shear stress between 0.4-0.6, and (2) correcting for the 
dependence of cell flux on flow rate (see Appendix A).   
Second, clinical ECP exposure plates were pre-coated with platelets.   
Third, a “wash-out” step, in which elevated shear forces were applied to disassociate 
any platelet-attached monocytes, was applied for approximately 30 seconds at the 
conclusion of the ECP procedure.   
Fourth, since the previously described interactions with platelets are independent of 
UVA energy, and indeed, all the previously described results using the model were 
carried out in the absence of both 8-MOP and UVA, we simplified the clinical ECP 
system by eliminating the use of 8-MOP and UVA energy.  
Using this enhanced ECP system, 50.5 + 11 % of the treated monocyte population was 




of HLA-DR and cytoplasmic CD83, compared with 30.0 + 6% in traditional ECP, and 
5.25 + 2% of the non-treated control (Figure 8).      
 
 
Figure 8. Enhancement of traditional ECP.  The traditional ECP system was modified 
based on principles presented in this thesis to maximize platelet-monocyte interactions: 
(1) flow rate was changed from 100 ml/min to 24 ml/min; (2) exposure plate was pre-
coated with platelet rich plasma; (3) theoretically adherent cells were “washed out” 
with application of high shear stresses at the conclusion of treatment; (4) the use of 8-
MOP and UVA energy was discontinued.  Each of the three conditions on the x-axis 
were conducted side-by-side using samples obtained from the same subject, repeated 
and averaged for 4 subjects.  Control samples did not receive exposure to the ECP 
apparatus, but underwent the identical preparation steps which treated samples 









Our collective data reveal that platelets substantially contribute to signaling the 
induction of monocyte-to-DC differentiation.  By providing a setting in which ample 
monocyte-platelet interactions may occur, ECP may be co-opting and enhancing a 
natural physiologic mechanism for DC generation.  The rapidity and efficiency of this 
cellular conversion, in the absence of exogenously added growth factors and without 
the need for lengthy tissue culture, are consistent with the timeframe and conditions 
normally operative in vivo in the initiation of DC responses. 
Previous studies on ECP had revealed that the procedure causes large scale conversion 
of passaged blood monocytes into leukocytes with features typical of DC, in terms of: 
genetic expression, phenotype, and functional capabilities [1, 49].  This generation of 
DC, cells known to orchestrate the body’s immune response, may be responsible for 
the therapy’s clinical effectiveness.  A lack of mechanistic knowledge regarding how 
ECP induced DC-differentiation has precluded introduction of scientifically-based 
modifications.  Enhancement of the therapy could potentially expand its therapeutic 
scope to encompass a much broader range of cancers beyond CTCL.   
Our results are consistent with the following mechanistic steps, in terms of DC 
generation, taking place in ECP (see Figure 9, pg 44): (1) plasma fibrinogen first coats 
the plastic surface of the flow chamber;  (2) through its IIb3 receptor, unactivated 
platelets bind and adhere to the plastic-immobilized fibrinogen; (3) platelets become 




transiently bind p-selectin via PSGL-1, causing partial monocyte activation and 
integrin receptor conformational changes; (5) partially-activated monocytes, now 
capable of further interactions, bind additional platelet-expressed ligands, including 
those containing RGD domains; (6) finally, so influenced, monocytes efficiently enter 
the DC maturational pathway. 
The above mechanism is in agreement with both our results as well as known 
physiologic interactions reported elsewhere.  For instance, physiologically, healthy 
endothelium acts as an inhibitor of platelet adhesion [50, 51]; since ECP involves 
platelet-flow in the absence of this inhibition, it is reasonable to expect that platelets 
would adhere and activate upon contact with the ECP plate’s surface, as we have 
observed.   
Platelet activation is a critical step, as it opens the possibility of a number of monocyte-
platelet interactions taking place within the ECP apparatus.  Upon platelet activation, 
intracellular alpha and delta granules containing preformed proteins are translocated to 
the plasma membrane, and along with other mechanisms, result in the increased 
expression and/or secretion of an array of proteins capable of interacting with 
monocytes [52].  These proteins include: p-selectin, fibronectin, fibrinogen, CD40L, 
TNF Superfamily 14, TREM-1 ligand, IGF-1, platelet derived growth factor (PDGF), 
platelet factor 4 (PF4), TGF-, thrombospondin, RANTES, and CXCL10. 
In order for monocytes to receive the majority of these signals from the platelet, the 
monocyte must be partially activated, that is, they must have the suitable receptors 




monocytes is PSGL-1, a proteoglycan capable of interacting with P-selectin expressed 
by activated platelets [53].  Our findings show that monocyte binding to platelet p-
selectin resulted in monocyte integrin conformational changes, thereby allowing the 
monocyte to receive additional signals from the platelet downstream.  Furthermore, 
blocking p-selectin resulted in a complete attenuation of monocyte to DC 
differentiation.  Other studies have reported that the PSGL-1:p-selectin interaction 
results in increased expression and activation of the 41 and M2 integrins [24, 25], 
NFB activity [54], TNF- secretion [54], Tissue Factor expression [55, 56], MCP-1 
secretion [54, 57], and increased chemokine synthesis [58].   
Downstream of p-selectin, platelet ligands containing RGD domains are likely 
involved in interactions with monocytes.  Our results indicate that blocking RGD 
binding-sites results in a significant decrease in the long-duration monocyte-platelet 
interactions.  Proteins such as fibrinogen and fibronectin contain RGD domains and are 
expressed by activated platelets at a high density.  Monocyte integrins 51, M2, 
V3, V1, and others are capable of binding RGD domains, with fibronectin and 
fibrinogen serving as principle ligands for 51 and M2, respectively [48].  Integrin 
signaling is well known to affect gene expression, cell growth, activation, and survival 
[59].   
In addition to RGD-containing proteins, other possible platelet interactions that could 
contribute to DC induction include CD40L with monocyte CD40.  CD40L has been 
previously shown to serve as a potent activator of monocytes, and under the right 




superfamily 14, expressed by activated platelets, has been shown to interact with 
monocytes and induce proinflammatory cytokine profiles, as well as cause partial DC 
maturation in certain settings [35-37].  TREM-1, a ligand on monocytes, is known to 
play a large role in LPS-induced inflammation [32, 38]; interestingly, the ligand can 
also engage TREM-1L expressed by activated platelets [60].  PDGF, PF4, TGF-, 
RANTES, and other platelet derived products have all also been shown to induce pro-
inflammatory changes in monocytes [40-44].  Additional studies will be required to 
clarify the potential importance of these and/or other platelet ligands in facilitating 
monocyte-to-DC differentiation. 
The clinical success of the ECP system may very well lie in its ability to provide an in 
vitro environment for monocyte-platelet interactions to take place.  Removing platelets 
from the confines of the endothelium places them in a pro-adhesive state in which they 
readily become activated.  Furthermore, the flow component of ECP provides the 
natural shear forces necessary for platelet-monocyte bond formation to form.  Without 
shear forces, bonds that evolved to form in flowing arteries and capillaries are less 
energetically favorable and unlikely to form [44, 45].  We found that activated platelets 
alone, without flow, were not sufficient to cause DC differentiation.   
The rapidity and efficiency with which this induction occurs suggests a physiologic 
role for the mechanism.  Why platelets, well known for their roles in hemostasis and 
thrombosis, may have evolved to play a DC-inducing role can only be speculated.  It 
should be pointed out though, that at both the cellular and molecular levels, many 




leads to an imbalance of procoagulant to anticoagulant properties of the local 
endothelium, leading to platelet accumulation and activation [31-33].  Furthermore, 
platelets, due to the physical forces of flow and the phenomenon of radial dispersion, 
circulate in blood at a radial position closer to the endothelium than any white blood 
cell [61].  In this sense, platelets can be viewed as surveying endothelium for signs of 
chronic infection/inflammation.    From this position, we propose that platelets are 
ideal for recruiting and activating a few monocytes to enter the tissue and differentiate 
to APC that can orchestrate the immune system’s adaptive response.  This pivotal role 
of the platelet would only add to the relatively recent body of literature placing it as a 
central player in numerous inflammatory processes [62-65]. 
The implications for potentially exploiting the mechanism described in this manuscript 
are tremendous.  It may be possible with future advancements to generate DC for 
treatment of other hematologic malignancies beyond CTCL, as well as solid tumors.  
Furthermore, the ease with which this mechanism produces DC raises the possibility 









Figure 9.  Proposed mechanism for induction of monocyte-to-DC differentiation.  
Based on data presented in this thesis, the following sequence of events are postulated: 
(1) plasma fibrinogen coats the plastic surface of the flow chamber;  (2) through its 
IIb3 receptor, unactivated platelets bind to the gamma-component of immobilized 
fibrinogen; (3) platelets become activated and instantaneously express preformed p-
selectin and other proteins; (4) passaged monocytes transiently bind p-selectin via 
PSGL-1, causing partial monocyte activation and integrin receptor conformational 
changes; (5) partially-activated monocytes, now capable of further interactions, bind 
additional platelet-expressed ligands, including those containing RGD domains; (6) 
finally, so influenced, monocytes efficiently enter the DC maturational pathway within 
18 hours.  Note that step (1) above may be replaced physiologically by inflammatory 
signals from tissue acting on local endothelium, causing it to recruit and activate 






Please see attached CD-ROM for access to the following supplemental material: 
 
Supplement 1: video, initial studies using ECP model 
Supplement 2: video, effect of platelet density on monocytes 









Initially developed as a means of exposing T-cells to specific titratable doses of UVA 
energy, the development of ECP coincidentally generated a system which subjected 
human cells to complex flow dynamics.   An in-depth understanding of the 
mathematics governing the flow dynamics in ECP is therefore central to the 
development and testing of any hypothesis involving cellular interactions occurring 
within the ECP apparatus.   
Principles key to understanding flow dynamics in ECP are derived and presented for 
the first time in this section, along with descriptions of how, in theory, certain easily 
modified ECP parameters can influence this dynamic system at the mathematical level. 
Mathematically Modeling ECP 
 
Figure A1.  Therakos ECP plate. 
The ECP exposure plate used clinically by the Therakos System is shown above.  




through this plate, which holds approximately 70 ml of fluid at a given time point.  The 
plate can be described as consisting of 7 linear segments measuring 25cm (length) by 
3.0 cm (width) by 0.1 cm (depth), connected by 6 regions containing a curvature of 
approximately 0.33 cm
-1
 (note: curvature is equal to approximately the inverse of the 
radius, as measured from the center of the channel).  Using a Cartesian coordinate 
system, from this point forward this text will refer to the direction of flow as occurring 
in the x-direction; the z-axis existing perpendicular to the x-axis and the two greatest 
surfaces of the plate, and the y-axis existing perpendicular to both x and z as defined 
above. 
As with any system involving fluids, flow will occur down a potential energy gradient 
as long as resistance is finite.  In the case of ECP, this potential energy gradient is 
generated by a peristaltic pump, which for simplicity will be modeled as generating a 
driving force which does not vary with time.   
Although the potential energy difference (i.e. driving force) is the same for all 
molecules, it can be hypothesized that not all molecules in flow will develop the same 
velocity in the steady state.  Solvent molecules interact with each other through H-
bonds and Van dar waals forces.  The pressure difference generated by the pump in the 
x-direction essentially leads to a force on the molecules which opposes the inter-
solvent forces.  If the force generated by the pressure difference is greater than that of 
adhesion, rows of molecules will accelerate in the x-direction.  The force generated by 
the pressure difference will be the same on all molecules regardless of its y-coordinate, 




to its neighbors, and therefore each row should develop the same acceleration and 
velocity relative to its neighbors.  As Figure A2 illustrates, the equal relative velocities 
of one row with respect to its neighboring row generates an interesting velocity profile 
with respect to a common, stationary point of reference: the velocity of molecules 
relative to this stationary point increase as the number of rows separating the stationary 
point and molecule of interest increases.  In the hypothetical situation depicted in 
Figure A2, the pressure difference generated by the ECP pump results in one row 
overcoming inter-molecular forces to a degree that allows it to move past its 
neighboring row at a velocity of 2 x-units per second.  These small displacements add 
up, such that relative to the stationary wall, a molecule just 8 rows away will be 





Figure A2.  Velocity increases as distance from wall increases. 
  
 
To describe the phenomena explained above and other parameters of flow in useful 
quantitative terms, we look to the Navier-Stokes equations for help in the derivation of 
parameters particular to the ECP system we are studying.  Navier-Stokes equations are 
non-linear partial differential equations that arise from applying Newton’s second law 
of motion to fluids; the equations describe fluid motion, and are particularly useful in 
the case of one-dimensional flow.  Their derivation has been described elsewhere [66] 




























































































































   
In the above equations:  = density; u and v = the Cartesian components of velocity 
along the x and y axes, respectively; p = pressure; T=temperature; t=time; e = specific 
internal energy (= internal energy per unit mass of fluid = CvT, where Cv is the 
specific heat at constant temperature); ho = specific total enthalpy (= total enthalpy per 
unit mass).  Additionally, the stresses due to viscosity above, txx, txy, and tyy, are related 






































































































Because of the nonlinear nature of the Navier-Stokes equations, exact solutions are 
difficult to obtain.  In the case of applicability to ECP, high level of simplification can 
be applied to move towards exact solutions.  First, we can assume that a steady state is 




above equations can be removed.  Second, we assume that viscosity remains constant 
throughout the experiments.    
Third, and most importantly: as described above, the Therakos ECP plate consists of 7 
linear segments connected by 6 segments with significant curvature.  If we elect to only 
model the centers of the linear segments, far enough from the segments of curvature to 
assume developed flow, then Newtonian laminar flow can be assumed.  In these 
conditions, flow occurs only in the x-direction, dropping all velocity components from 
the y and z-directions for the above Naiver-Stokes equations.  Furthermore, since the 
cross-sectional dimension of linear segments, 30 mm by 1 mm, consists of a 
significantly greater width than depth, we assume that fluid segments behave as if the 
z-dimension is infinite, an assumption that only breaks down at the extremes of z.  
With these assumptions applied to the Naiver-Stokes equations, we obtain the 































Integrating the second equation above twice with respect to y, and treating dp/dx as a 

















Defining y = 0 to be the point equidistant from both plates, and defining 2h as the total 
distance between plates, and assuming u = 0 at y = +/- h, the coefficients for the above 




























Examination of the above equation reveals that velocity is dependent on the negative 
square of distance from the center of the flow stream, as depicted for clarity in Figure 
A3.  This variation is consistent with that predicted conceptually in the previous 
section and outlined back in Figure A2. 
 





While these descriptions are helpful in understanding flow occurring in ECP, by 
defining a few additional parameters, these findings can be extended to help describe 
the complex interactions occurring between the cellular components of ECP.  
Shear rate is simply the difference in velocity of one fluid layer in relation to its 
adjacent fluid layer, represented graphically by Figure A4, and mathematically by the 
subsequent equation.   
 
Figure A4. Sheer Rate in the x direction 
 










While we know the peristaltic pump in ECP generates a force driving one layer past 
another, Newton’s second law, F=Ma, indicates that the net force must be equal to zero 
if the fluid is to travel at a constant velocity as it does in ECP.  Therefore, an opposing 
force or source of energy dissipation must exist.  This phenomenon is called shear 
stress,, and is due to molecular collisions occurring between adjacent layers.  These 
non-elastic molecular collisions result in transfer of momentum.  As can be visualized 




occurring per unit time, which itself is dependant on the velocity difference, or shear 
rate, between the two layers of fluid.  Thus,  
dy
(y)dv
  α  τ(y)
x
 
This proportionality constant is referred to as fluid viscosity, , and is dependent on 
composition of the fluid: the density or molecules, their molecular weight, their shape, 
etc.  After addition of this proportionality constant, and substituting in the velocity 






























As this equation shows, shear stress varies linearly with distance from the center of 
flow.  Figure A5 below graphically represents and compares the y-dependence of 
velocity, shear rate, and shear stress. 
    
Figure A5. Dependence of velocity, shear rate magnitude, and shear stress 






Shear stress is a parameter of critical importance in determining what bonds can form 
in flow [44].  Because of this importance, it was essential for us to be able to express 
this parameter as a function of parameters more easily described, such as volumetric 
flow rate, Q.  In order to do this, we first recognize the conceptual association between 
volumetric flow rate and the velocity equation derived earlier: volumetric flow rate is 
the sum all volume elements passing through regions of size dydz, thus, we can obtain 
Q simply by integrating the velocity equation derived earlier with respect to dy and dx; 























































   
Substituting this value back into shear rate equation derived above, we obtain the shear 






   τ(y)

  
Thus far the fluid described has consisted of simply one type of molecule, the solvent.  
The position of particles, or in ECP’s case, white and red cells, can be ascertained by 
examination of the solution’s shear rate dependence on y.  Particles added to a solution 
will initially be randomly distributed, however, it can be hypothesized that theoretically 
once flow is initiated, particles will begin to have an increased probability of migrating 
towards the center of flow, or towards y = 0.  This theoretical distribution is based on 




displacements.  The number of collisions per unit time at any given distance, y, from 
the center of flow is dependent on the relative difference in velocity between two 
adjacent layers, i.e. the shear rate.  Since shear rate has been calculated in the previous 
section to be highest near the walls and lowest at the center of flow, particles are at a 
greater likelihood to collide and undergo random displacements when in the periphery; 
should a random displacement place the particle near the center of flow, it’s chances of 
another collision will be lower than if the random displacement places it further from 
the center.  Thus, since the probability of receiving a random displacement is greater in 
the periphery than center, the flux of particles into the center will be greater than the 
flux out of the center.  In other words, the conditions of flow in ECP will lead to the 
tendency of particles to undergo an organized distribution towards the center of flow.        
ECP involves the flow of many cell types, including red cells, monocytes, 
lymphocytes, neutrophils, and platelets.  These cell types have different properties such 
as size, density, mass, deformability, and so forth.  Since the center of the laminar flow 
stream in ECP is a finite space, it is not possible for all cells to simultaneously reside 
here.  To theorize on which cells will preferentially occupy this preferred region, we 
look to the laws of thermodynamics.  It can be deduced from the laws of 
thermodynamics that fluids in flow look to obtain the state of least entropy, S, 
generation [67].  The classic definition of entropy change is simply the heat transferred 
divided by the temperature at which that heat was transferred, integrated from the start 




Entropy changes can be quantified in fluids without regard to temperature changes by 
tying together a sequence of logical statements.  Since in the steady state, there is no 
acceleration of fluid in the x direction, all work done in the x direction must be 
balanced by energy dissipated by the frictional shear stress.  This connects heat transfer 
to the previously described shear stress, which is itself connected to the work done on 
the fluid by the pump (since the energy transfers must be equal if the fluid is to remain 
at the steady state).  Since work = force * distance, and distance = shear rate * dx * 
time, with the work of some basic algebra and integration, we can relate changes in 







This equation allows one to see that entropy changes will be proportional to the square 
of shear stress, which Figure A5 above shows to be a minimum at the center of flow 
and maximum at the walls.  Therefore, entropy generation will be minimal in the state 
which consists of the most massive particles occupying the center of flow, where their 
collisions would occur at the lowest relative velocity and results in minimal energy 
transfer. 
This principle is critical to understanding flow dynamics in ECP.  It dictates that the 
cells with the greatest probability of interaction with the plastic plate and its absorbed 
proteins are those cells which are excluded from the thermodynamically preferred 
center of flow.  Furthermore, this principle allows one to better predict, based on 




interactions.  For instance, with all other parameters held constant, increasing 
hematocrit may paradoxically increase the number of white-cell interactions occurring 
at the plate wall.  This is because an increasing density of red cells would in-effect 
better exclude white cells from the center of flow, pushing them to the periphery.  
Additionally, with all other parameters held constant, increasing shear rate to certain 
levels could decrease the number of white-cell interactions at the plastic wall for 
reasons other the dependence of these interactions on shear stress.  Individual red cells 
are significantly smaller than lymphocytes and granulocytes, however, under low to 
medium range shear rates, red cells are known to aggregate with one-another, forming 
stacks of red cells known as rouleaux.  These bodies are significantly greater in size 
and mass compared to white cells, and therefore are energetically favorable in the 
center of flow compared to white cells.  When shear rates extend to beyond that of a 
critical value (dependent on other variables), the intercellular interactions maintaining 
these red cell formations are overcome, and the cells become individual entities.  In 
these conditions, white cells are larger and more massive, and therefore become the 
cell more energetically favorable for occupation of the center of flow. 
 
Enhancing ECP 
As evident from the explained derivations, the above equations and concepts hold for 
any flow system consisting of constant volumetric flow between parallel plates with 
the z-dimension significantly larger than the y-dimension.  It is therefore fairly easy to 




In order to enhance the flow conditions of ECP to maximize platelet-monocyte 
interactions, we first recognized that the number of platelet-monocyte interactions per 
unit time (Itis the product of both the likelihood that a monocyte will interact with a 
platelet if within binding distance (PCT), and the flux of monocytes which are placed 
within a binding distance per unit time ( baQ ).  PCT is a function of shear stress, as 
revealed in the results section.  Shear stress derived earlier can be written as a function 
of only Q when y is appropriately set equal h (wall shear stress).  In summary, platelet-
monocyte interactions per unit time can be written as: 
))(()()( QPCTQQQI baT   
))(( QPCT  can be obtained using the experimental data presented in the results section on 
the platelet-monocyte interaction dependence on wall shear stress, extrapolated to have Q 
represent the necessary flow rate in the Therakos system (using equation derived earlier).  
)(QQba can be calculated theoretically by integrating the appropriate equations presented 
earlier over a theoretical binding distance.  In this manner, )(QIT is calculated to be at a 
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